FDA approves ‘artificial retina’ to provide limited vision for blind
The agency approved Argus II, made by Second Sight Medical Products, to treat people with severe retinitis pigmentosa, a group of inherited diseases in which photoreceptor cells, which take in light, deteriorate.
The New York Times
The Food and Drug Administration (FDA) on Thursday approved the first treatment to give limited vision to people who are blind, involving a technology called the “artificial retina.”
With it, people with certain types of blindness can detect crosswalks on the street, burners on a stove, the presence of people or cars, and sometimes oversize numbers or letters.
The artificial retina is a sheet of electrodes surgically implanted in the eye. The patient is also outfitted with a pair of glasses with an attached camera and a portable video processor. These elements together allow visual signals to bypass the damaged portion of the retina and be transmitted to the brain. The FDA approval covers this integrated system, which the manufacturer calls Argus II.
With the artificial retina or retinal prosthesis, a blind person cannot see in the conventional sense but can identify outlines and boundaries of objects, especially when there is contrast between light and dark: fireworks against a night sky or black socks mixed with white ones in the laundry.
“Without the system, I wouldn’t be able to see anything at all, and if you were in front of me and you moved left and right, I’m not going to realize any of this,” said Elias Konstantopolous, 74, a retired electrician in Baltimore, one of about 50 Americans and Europeans who have been using the device in clinical trials for several years.
He said it helps him differentiate curbs from asphalt roads and detect contours, but not details, of cars, trees and people.
“When you don’t have nothing, this is something,” Konstantopolous said. “It’s a lot.”
The FDA approved Argus II, made by Second Sight Medical Products, to treat people with severe retinitis pigmentosa, a group of inherited diseases in which photoreceptor cells, which take in light, deteriorate.
The first version of the implant had a sheet of 16 electrodes, but the current version has 60. A tiny camera mounted on eyeglasses captures images, and the video processor, worn on a belt, translates those images into pixelized patterns of light and dark. The processor transmits those signals to the electrodes, which send them along the optic nerve to the brain.
About 100,000 Americans have retinitis pigmentosa, but initially between 10,000 and 15,000 will likely qualify for the Argus II, according to the company. The FDA says up to 4,000 people a year can be treated with the device. That number represents people who are older than 25, who once had useful vision, have evidence of an intact inner retinal layer, have at best very limited light perception in the retina and are so visually impaired that the device would be an improvement. Second Sight will begin making Argus II available this year.
Experts said the technology holds promise for other people who are blind, especially those with advanced age-related macular degeneration, the major cause of vision loss in older people, affecting about 2 million Americans. About 50,000 of them are impaired enough that the artificial retina would be helpful, said Dr. Robert Greenberg, Second Sight’s president and chief executive.
In Europe, Argus II received approval in 2011 to treat a broader group of people, those with severe blindness caused by any type of outer retinal degeneration, not just retinitis pigmentosa. In the United States, additional clinical trials need to be completed before the company can seek broader FDA approval.
Eventually, Greenberg said, the plan is to implant electrodes directly into the brain’s visual cortex.
“That would allow us to address blindness from all causes,” he said.
Initially, the artificial retina will be available at seven hospitals in five states: New York, California, Texas, Maryland and Pennsylvania. It will cost about $150,000, not including the surgery and training sessions to use the device. Second Sight said it was optimistic that insurance would cover it.
The Argus II has had relatively few safety problems, mostly post-surgical infections and occasional erosions of a thin layer in the eye that covered the implant. Those problems have been addressed, Greenberg said, and only two people needed to have the implant removed. An FDA advisory panel voted unanimously in September to recommend approval, finding that benefits outweighed the risks.
Some patients experience more improvement than others, for reasons the company has not been able to determine. Kathy Blake, of Fountain Valley, Calif., said she has had success with a Second Sight exercise to see if patients can identify large numbers or letters on a computer screen.
Barbara Campbell, 59, relishes how the device helps her navigate Manhattan streets, locate her bus stop and spot her apartment building’s foyer light while riding in a taxi.
Most exciting, though, is how it enhances her experience of museums, theater and concerts.
At a Rod Stewart concert, “I could definitely see his hair,” she said, which was white-blond under the lights. At a concert by Diana Ross, even though Campbell sat far from the stage, she said Ross “was wearing a sparkly outfit, and I could see her.”
No such luck at a performance by James Taylor, though. His low-key clothing created no contrast for the artificial retina to register. Alas, Campbell said, “He wasn’t so sparkly.”